Cladribine
Cladribine is a deoxyadenosine analog that exhibits immunosuppressive and anticancer chemotherapeutic activities. Cladribine is used clinically to treat hairy cell leukemia and has shown mixed results as a potential treatment for multiple sclerosis. Cladribine induces apoptosis in monocyte-derived dendritic cells. Across many cellular models, this compound decreases levels of circulating B and T lymphocytes and inhibits growth of both proliferating and quiescent cells. As a nucleoside analog, cladribine inhibits DNA polymerase and ribonucleotide reductase, suppressing DNA repair and synthesis.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18852356
| Cas No. |
4291-63-8 |
|---|---|
| Purity |
≥98% |
| Formula |
C10H12ClN5O3 |
| Formula Wt. |
285.69 |
| IUPAC Name |
(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol |
| Synonym |
2-CdA, 2-Chlorodeoxyadenosine |
| Melting Point |
210-220C |
| Appearance |
White to off white powder |
Singh V, Prajeeth CK, Gudi V, et al. 2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells. Clin Exp Immunol. 2013 Aug;173(2):288-97. PMID: 23607690.
Comi G, Hartung HP, Kurukulasuriya NC, et al. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Pharmacother. 2013 Jan;14(1):123-36. PMID: 23256518.
Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011 Jan-Feb;34(1):28-35. PMID: 21242742.
Robak T, Korycka A, Robak E. Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies. Recent Pat Anticancer Drug Discov. 2006 Jan;1(1):23-38. PMID: 18221024.
